![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will advance Lycia's lead programs, including next-generation degradation approach leveraging lysosomal targeting chimeras, or LYTACs, into the clinic for autoimmune and inflammatory diseases.
Lead Product(s): Lysosomal-targeted Chimeras
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Venrock Healthcare Capital Partners
Deal Size: $106.6 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 13, 2024
Details:
Under the collaboration, Lycia will leverage Nona's proprietary Harbour Mice® HCAb fully human antibody transgenic mice platform to discover novel antibodies for its LYTAC protein degrader therapeutics.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Nona Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 04, 2023
Details:
The company’s lysosomal targeting chimeras, or LYTAC, platform can be extended to several therapeutic modalities, including antibodies and small molecules, with the potential to inhibit many targets.
Lead Product(s): LYTAC-based Therapeutics
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Redmile Group
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 09, 2021
Details:
Under the terms of the agreement, the companies will utilize Lycia's LYTAC platform to discover and develop novel degraders for up to five targets that aim to address key unmet medical needs in Lilly's therapeutic areas of focus, including immunology and pain.
Lead Product(s): LYTAC-based Therapeutics
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,635.0 million Upfront Cash: $35.0 million
Deal Type: Collaboration August 25, 2021
Details:
Proceeds are being used to develop lysosomal targeting chimeras, or LYTACs, as therapeutics for a broad set of currently intractable cell surface targets.
Lead Product(s): Lysosome targeting chimeras
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 09, 2020